Brain Tumour Research Novel Therapeutics Accelerator

We’re thrilled to share that Reglagene was selected to participate in the Brain Tumour Research Novel Therapeutics Accelerator on November 6th in Boston! Our CEO, Richard Austin, and Doris Sanchez, our regulatory and clinical development strategist, had the privilege of engaging with leading experts in the field, including KOLs, and preclinical and clinical development specialists. Discussions centered around our flagship program, RGN6024, a novel approach to tackling brain cancers.

This opportunity provided valuable insights and reinforced our commitment to advancing innovation in brain cancer therapies. Thank you to Charlotte Aitken from the Tessa Jowell Brain Cancer Mission and the participating experts for fostering such an impactful exchange of ideas. Together, we’re making strides toward better outcomes for patients.